NT 100

Drug Profile

NT 100

Alternative Names: NT-100

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nora Therapeutics
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Infertility therapies; Neuroprotectants
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Female infertility

Most Recent Events

  • 25 Aug 2016 Phase-II development is ongoing in United Kingdom
  • 06 Jun 2016 Nora Therapeutics completes the phase III RESPONSE trial for Female infertility in United Kingdom (EudraCT2014-000084-40)
  • 01 Sep 2015 Nora Therapeutics completes a phase II follow-up trial in Female infertility in USA (NCT01978561)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top